Intervacc has presented new findings at the ACVIM Forum in the United States

Stockholm, June 13th, 2024 – Intervacc AB (publ) has presented new reports highlighting the importance of vaccination to disease control strategies and the safety and efficacy of Strangvac in the field at the American College of Veterinary Internal Medicine (ACVIM) forum in Minneapolis, USA. ACVIM is the largest veterinary organization in the world and the annual forum brings together veterinarians to be updated on research findings in veterinary medicine.

The following three posters were presented to the participants:

• Horses vaccinated with Strangvac did not develop clinical signs of disease, despite serological evidence that they had been exposed to S.equi. This is a collaboration between SVA, KI, SLU, Intervacc, and Mybac-Vettech.
• Vaccination with Strangvac was immunogenic and caused transient side effects in horses. A collaboration between KI, the National Equestrian Centres, SVA, Intervacc, and Mybac-Vettech.
• Sequencing the S.equi genome highlighted that screening, quarantine and vaccination are likely to have the greatest impact in preventing strangles. A collaboration between the Royal Veterinary College, the University of Cambridge, Intervacc, Surveillance of Equine Strangles, and EIDS.

“Horses all over the world are affected by strangles and it is extremely important to communicate these findings from Europe to raise awareness of this disease and the role vaccination plays in preventing its spread,” said veterinarian Emma Hartman, Global Product Manager at Intervacc. “We are working with veterinarians to improve our understanding of how Strangvac is used in different situations to optimize the protection of horses against this terrible disease.”

For more information please contact:  

Jonas Sohlman, CEO
E-mail: jonas.sohlman@intervacc.se
Phone: +46 (0)8 120 10 600

The information was submitted for publication, through the agency of the contact person set out above on June 13, 2024, 11.15 CET.

About equine strangles

Strangles, caused by the bacterium Streptococcus equi, is a severe, common and highly contagious infectious disease that can kill up to 10% of horses. Strangles is endemic in horse populations worldwide, with the exception of Iceland.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10